Week 6 — Oct 19: Separation Methods

(Lecture 6.) Spectroscopy measured a property of a whole sample. Most real pharmaceutical questions — how much API, and what else is in there — need the components pulled apart first. Chromatography and electrophoresis are how the majority of assay and impurity methods in a QC lab actually work, so this is the analytical core of the course, compressed into one intensive week.

The one idea

A separation is a controlled competition: every component partitions back and forth between a stationary and a mobile phase, and small reproducible differences in how long each stays stuck are amplified, over a column, into baseline resolution. A separation method is not discovered and then validated — it is designed against a target and defended across a region of conditions.

The four numbers that describe a peak pair

Practical reading: once k is reasonable, chasing N has square-root returns while a small gain in α moves resolution a lot. Method development is mostly a search for selectivity.

Van Deemter — why peaks are as wide as they are

Plate height H = A + B/u + C·u vs linear velocity u:

That last row is the whole case for UHPLC: the optimum shifts to higher flow and shorter columns — same resolution in a fraction of the time, at the cost of back-pressure and tighter demands on system dispersion.

Modes, detectors, and the other separation techniques

Detectors: UV / diode array (the workhorse; DAD gives peak purity), fluorescence (sensitive, selective), refractive index (universal-ish, insensitive), ELSD / charged-aerosol (CAD) (near-uniform response for non-volatiles), MS (Week 8).

TLC is not obsolete — cheap, parallel, compendial for many identity tests; HPTLC adds densitometry. Capillary electrophoresis separates by charge-to-size in an applied field, very high efficiency, tiny volumes; its modern importance is in large molecules (CE-SDS, icIEF, oligonucleotides).

The method-development workflow

Isocratic vs gradient: isocratic is simple and reproducible but has a narrow elution window; a gradient gives constant peak width and much higher peak capacity, which is why impurity-profiling methods are gradients — at the cost of re-equilibration time and dwell-volume sensitivity (a transfer hazard).

The stability-indicating method

Where Q1 and separations meet:

1. Force degradation (acid, base, oxidation, heat, humidity, light) to generate the degradants the method must see.
2. Resolve every degradant from the API and from each other, with margin.
3. Prove specificity — DAD peak purity on the API; confirm with an orthogonal method or LC–MS.
4. Check mass balance — assay loss should equal the sum of degradation products; a gap means a degradant you are not seeing.
5. Lock system suitability around the real critical pair — which forced degradation has now identified.

Large molecules — one protein, many separations

A small molecule needs one assay/impurity method. A monoclonal antibody needs a panel, because “purity” has several independent meanings:

Together these are the analytical basis for comparability (Q5E). These methods largely replaced hand-poured gels (SDS-PAGE, IEF) — the science barely changed, but a capillary run gives quantitative integration, real system suitability, and a Part 11 audit trail that a stained gel image cannot. Week 12 takes the large-molecule panel much further.

The wet-chemistry workhorses

Not everything is an instrument method. These are on almost every specification:

System suitability — the running proof

A validated method proves the separation can work; system suitability proves it is working, now, before any sample result is trusted: resolution of the critical pair (primary), tailing factor, plate count, retention reproducibility, replicate-injection %RSD (e.g. ≤ 2.0% for assay), and S/N at the reporting threshold. Fail it and no data from that run is usable — a specification acting as a real-time control, not paperwork.

Worked case — the specificity trap

A stability-indicating assay reports 99.1% — in spec, batch released. Two years later a longer-gradient, different-selectivity method finds a degradation product had been co-eluting under the API peak the whole time; the true assay was 96.8% and a specified impurity was over its limit.

Nothing looked wrong. Tailing, %RSD, system suitability all passed — because system suitability was built around the known critical pair, and this degradant wasn’t in it. What would have caught it: DAD peak purity, an orthogonal method in development, and mass balance (Q1) — the assay loss didn’t match the sum of impurities, and that gap was the tell. Straight back to risk: a separation’s most dangerous failure mode is the impurity it was never designed to resolve.

Where the analyst sits

Development software and closed-loop systems will optimise a separation against whatever critical pair you give them. Choosing the right critical pair — knowing, from the degradation chemistry and the synthesis, which impurity is most likely to hide — is analytical judgment, as is reading a chromatogram as a story about a sample. That is the STEAM “A”. The refrain: science → evidence → reduced uncertainty → control → regulatory confidence → patient trust.

For discussion

• You can double N by doubling column length (and run time), or improve α from 1.05 to 1.10 by changing the mobile-phase pH. Which gains more resolution, and why is that the general rule?
• A method transfers from an old HPLC to a UHPLC and the critical pair partly merges. What changed, and what would you check first?
• System suitability passed on a run that we later learned gave a wrong result. Was the test inadequate, or is this an inherent limit? What would you add?
• Forced degradation produces a degradant that co-elutes with the API on every column you try. Walk through your options before accepting it as a method limitation.
• A monoclonal antibody passes CE-SDS, SEC, and CEX but the peptide map shows rising deamidation at one site over shelf life. Which specification should catch this?
• Karl Fischer and loss-on-drying give different numbers for the same sample. Which is right, and what does the difference tell you?

Source note. Chromatographic theory follows Snyder, Kirkland & Dolan, Practical HPLC Method Development, and Harris. Compendial: USP ⟨621⟩ (chromatography and system suitability), ⟨1058⟩ (instrument qualification), ⟨1053⟩ (CE), ⟨921⟩ (water determination), ⟨733⟩ (loss on ignition); Ph. Eur. 2.2.46 / 2.2.47 / 2.5.12. Validation and MODR tie to Q2 and Q14; the specificity case to Q1. (Instructor: this is a consolidation of what were two lecture weeks — decide what moves to a problem set, and confirm current ⟨621⟩ rules on adjusting a compendial method without revalidation.)

• ←5 · Oct 12
• 7 · Oct 26→